

Table S1. Antibiotic sensitivity and resistance markers of *K. pneumoniae* and *A. baumannii* isolated from patient 92/23's bronchoalveolar lavage sample. Determination of antibiotic sensitivity was performed on a BD Phoenix-100 automated bacteriological analyzer (BDBiosciences, San Jose, CA, USA) and data interpretation was conducted according to the installed EUCAST protocols.

Antibiotic	<i>K. pneumoniae</i>		<i>A. baumannii</i>	
	Susceptibility	MIC	Susceptibility	MIC
Amikacin	R	16 mg/L	R	>32 mg/L
Amoxicillin/Clavulanate	R	>32/2 mg/L	-	-
Ampicillin	R	>16 mg/L	-	-
Gentamicin	S	≤2 mg/L	R	>8 mg/L
Imipenem	R	>8 mg/L	R	>8 mg/L
Levofloxacin	R	>4 mg/L	R	>2 mg/L
Piperacillin/Tazobactam	R	>32/4 mg/L	-	-
Tobramycin	R	>8 mg/L	-	-
Trimethoprim/ Sulfamethoxazole	S	≤2/38 mg/L	R	>8/152 mg/L
Phosphomycin	S	≤16 mg/L	-	-
Cefazolin	R	>32 mg/L	-	-
Ceftazidime	R	>16 mg/L	-	-
Ceftriaxone	R	>4 mg/L	-	-
Ciprofloxacin	R	>1 mg/L	R	>1 mg/L
Ertapenem	R	>2 mg/L	-	-
Meropenem	R	>8 mg/L	R	>8 mg/L
Resistance marker	Extended-spectrum beta-lactamase (ESBL)		Carbapenemase producer (CARB)	
	Potential carbapenemase producer (ALERT1)		-	

MIC—minimum inhibitory concentration; R—resistant; S—sensitive.

Table S2. Antibiotic sensitivity and resistance markers of *K. pneumoniae*, *A. baumannii* and *P. aeruginosa* isolated from patient 62/22's bronchoalveolar lavage sample. Determination of antibiotic sensitivity was performed on a BD Phoenix-100 automated bacteriological analyzer (BDBiosciences, USA) and data interpretation was conducted according to the installed EUCAST protocols.

Antibiotic	<i>A. baumannii</i>		<i>K. pneumoniae</i>		<i>P. aeruginosa</i>	
	Susceptibility	MIC	Susceptibility	MIC	Susceptibility	MIC
Amikacin	R	>32 mg/L	S	≤8 mg/L	S	16 mg/L
Gentamicin	R	>8 mg/L	R	>8 mg/L	-	-
Imipenem	R	>8 mg/L	R	>8 mg/L	R	>8 mg/L
Levofloxacin	R	>2 mg/L	R	>2 mg/L	R	>2 mg/L
Meropenem	R	>8 mg/L	R	>8 mg/L	R	>8 mg/L
Trimethoprim/ Sul- famethoxazole	S	<2/38 mg/L	S	<2/38 mg/L	-	-
Ciprofloxacin	R	>1 mg/L	R	>1 mg/L	R	>1 mg/L
Piperacillin/ Tazo- bactam	-	-	R	>16/4 mg/L	R	>16/4 mg/L
Cefepime	-	-	R	>8 mg/L	R	>8 mg/L
Ceftazidime	-	-	R	>8 mg/L	R	>8 mg/L
Cefuroxime	-	-	R	>16 mg/L	-	-
Amoxicillin/ Clavu- lanate	-	-	R	>16/2 mg/L	-	-
Ampicillin	-	-	R	>16 mg/L	-	-
Tigecycline	-	-	S	2 mg/L	-	-
Cefazolin	-	-	R	>32 mg/L	-	-
Ceftriaxone	-	-	R	>4 mg/L	-	-
Ertapenem	-	-	R	>1 mg/L	-	-
Resistance marker	-	Extended-spectrum beta-lac- tamase (ESBL)		-	-	-
	-	Potential carbapenemase pro- ducer (ALERT1)		-	-	-

MIC—minimum inhibitory concentration; R—resistant; S—sensitive.

Table S3. Antibiotic sensitivity and resistance markers of *S. aureus* isolated from patient 62/22's bronchoalveolar lavage sample. Determination of antibiotic sensitivity was performed on a BD Phoenix-100 automated bacteriological analyzer (BDBiosciences, USA) and data interpretation was conducted according to the installed EUCAST protocols.

Antibiotic	<i>S. aureus</i>		Antibiotic	<i>S. aureus</i>	
	Susceptibility	MIC		Susceptibility	MIC
Levofloxacin	R	>4 mg/L	Rifampin	R	>2 mg/L
Ciprofloxacin	R	>4 mg/L	Teicoplanin	S	≤0.5 mg/L
Mupirocin	I	≤256 mg/L	Tetracycline	R	>2 mg/L
Vancomycin	S	1 mg/L	Tigecycline	S	0.5 mg/L
Gentamicin	R	>4 mg/L	Tobramycin	R	>4 mg/L
Daptomycin	S	1 mg/L	Trimethoprim/ Sulfa- methoxazole	S	<0.5/9.5 mg/L
Clindamycin	R	>1 mg/L	Phosphomycin	S	≤16 mg/L
Linezolid	S	2 mg/L	Fucidin	S	≤0.5 mg/L
Moxifloxacin	R	>2 mg/L	Quinupristin/ Dal- fopristin	S	≤0.5 mg/L
Oxacillin	R	>2 mg/L	Chloramphenicol	R	>16 mg/L
Penicillin	R	>0.25 mg/L	Erythromycin	R	>4 mg/L
Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)					
Resistance marker					
MecA-mediated resistant <i>Staphylococcus</i>					
<i>Staphylococcus</i> MLSb phenotype					

MIC—minimum inhibitory concentration; R—resistant; S—sensitive; I—intermediate.

Table S4. Antibiotic sensitivity and resistance markers of *K. pneumoniae* and *A. baumannii* isolated from patient 847/21's bronchoalveolar lavage sample. Determination of antibiotic sensitivity was performed on a BD Phoenix-100 automated bacteriological analyzer (BDBiosciences, USA) and data interpretation was conducted according to the installed EUCAST protocols.

Antibiotic	<i>K. pneumoniae</i>		<i>A. baumannii</i>	
	Susceptibility	MIC	Susceptibility	MIC
Amikacin	R	>32 mg/L	R	>32 mg/L
Amoxicillin/Clavulanate	R	>32/2 mg/L	-	-
Ampicillin	R	>16 mg/L	-	-
Gentamicin	R	>8 mg/L	R	>8 mg/L
Imipenem	R	>8 mg/L	S	0.5 mg/L
Levofloxacin	R	>4 mg/L	R	>2 mg/L
Piperacillin/ Tazobactam	R	>32/4 mg/L	-	-
Tigecycline	I	4 mg/L		
Tobramycin	R	>8 mg/L		
Trimethoprim/ Sulfamethoxazole	R	>8/152 mg/L	S	≤2/38 mg/L
Phosphomycin	S	32 mg/L		
Cefazolin	R	>32 mg/L	-	-
Ceftazidime	R	>16 mg/L	-	-
Ceftriaxone	R	>4 mg/L	-	-
Ciprofloxacin	R	>1 mg/L	R	>1 mg/L
Ertapenem	R	>2 mg/L	-	-
Meropenem	R	>8 mg/L	S	1 mg/L
Resistance marker	Extended-spectrum beta-lactamase (ESBL)		-	
	Potential carbapenemase producer (ALERT1)		-	

MIC—minimum inhibitory concentration; R—resistant; S—sensitive; I—intermediate.